NASDAQ:ADIL

Adial Pharmaceuticals Stock Earnings Reports

etoro logo Buy ADIL
*Your capital is at risk
$0.311
-0.0145 (-4.46%)
At Close: Nov 17, 2025

Adial Pharmaceuticals Earnings Calls

Sep 30, 2025
-$0.0800 (11.11%)
Release date Nov 13, 2025
EPS estimate -$0.0900
EPS actual -$0.0800
EPS Surprise 11.11%
Revenue estimate -
Revenue actual -
Jun 30, 2025
-$0.180 (18.18%)
Release date Aug 13, 2025
EPS estimate -$0.220
EPS actual -$0.180
EPS Surprise 18.18%
Revenue estimate -
Revenue actual -
Mar 31, 2025
-$0.340 (32.00%)
Release date May 14, 2025
EPS estimate -$0.500
EPS actual -$0.340
EPS Surprise 32.00%
Revenue estimate -
Revenue actual -
Dec 31, 2024
-$0.150 (60.53%)
Release date Mar 04, 2025
EPS estimate -$0.380
EPS actual -$0.150
EPS Surprise 60.53%
Revenue estimate -
Revenue actual -

Last 4 Quarters for Adial Pharmaceuticals

Below you can see how ADIL performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Dec 31, 2024 Beat
Release date Mar 04, 2025
Price on release $0.750
EPS estimate -$0.380
EPS actual -$0.150
EPS surprise 60.53%
Date Price
Feb 26, 2025 $0.83
Feb 27, 2025 $0.770
Feb 28, 2025 $0.785
Mar 03, 2025 $0.731
Mar 04, 2025 $0.750
Mar 05, 2025 $0.770
Mar 06, 2025 $0.750
Mar 07, 2025 $0.750
Mar 10, 2025 $0.720
4 days before -10.10%
4 days after -4.01%
On release day 2.65%
Change in period -13.71%
Mar 31, 2025 Beat
Release date May 14, 2025
Price on release $0.650
EPS estimate -$0.500
EPS actual -$0.340
EPS surprise 32.00%
Date Price
May 08, 2025 $0.620
May 09, 2025 $0.601
May 12, 2025 $0.611
May 13, 2025 $0.634
May 14, 2025 $0.650
May 15, 2025 $0.660
May 16, 2025 $0.658
May 19, 2025 $0.700
May 20, 2025 $0.727
4 days before 4.84%
4 days after 11.77%
On release day 1.54%
Change in period 17.18%
Jun 30, 2025 Beat
Release date Aug 13, 2025
Price on release $0.400
EPS estimate -$0.220
EPS actual -$0.180
EPS surprise 18.18%
Date Price
Aug 07, 2025 $0.387
Aug 08, 2025 $0.380
Aug 11, 2025 $0.374
Aug 12, 2025 $0.395
Aug 13, 2025 $0.400
Aug 14, 2025 $0.395
Aug 15, 2025 $0.394
Aug 18, 2025 $0.380
Aug 19, 2025 $0.370
4 days before 3.36%
4 days after -7.50%
On release day -1.38%
Change in period -4.39%
Sep 30, 2025 Beat
Release date Nov 13, 2025
Price on release $0.319
EPS estimate -$0.0900
EPS actual -$0.0800
EPS surprise 11.11%
Date Price
Nov 07, 2025 $0.326
Nov 10, 2025 $0.323
Nov 11, 2025 $0.332
Nov 12, 2025 $0.329
Nov 13, 2025 $0.319
Nov 14, 2025 $0.325
Nov 17, 2025 $0.311
4 days before -2.03%
4 days after -2.63%
On release day 1.91%
Change in period -4.61%

Adial Pharmaceuticals Earnings History

Earnings Calendar

FAQ

When is the earnings report for ADIL?
Adial Pharmaceuticals Inc. (ADIL) has scheduled its earnings report for Mar 03, 2026 before the markets open.

What is the ADIL price-to-earnings (P/E) ratio?
ADIL P/E ratio as of Nov 17, 2025 (TTM) is -0.90.

What is the ADIL EPS forecast?
The forecasted EPS (Earnings Per Share) for Adial Pharmaceuticals Inc. (ADIL) for the first fiscal quarter 2025 is -$0.0900.

What are Adial Pharmaceuticals Inc.'s retained earnings?
On its balance sheet, Adial Pharmaceuticals Inc. reported retained earnings of $0 for the latest quarter ending Sep 30, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT ADIAL PHARMACEUTICALS INC.
Adial Pharmaceuticals
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE